BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 10213974)

  • 1. [Present status of unsealed radioisotope therapy in Japan based on the nation-wide questionnaire].
    Oyamada H
    Kaku Igaku; 1999 Feb; 36(2):71-81. PubMed ID: 10213974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The present status of I-131 therapy for Graves' hyperthyroidism in Japan (survey by questionnaire)].
    Ikekubo K; Kusakabe K; Kanaya S; Ishikawa N; Nakada K; Mori Y
    Kaku Igaku; 2003 Nov; 40(4):457-63. PubMed ID: 14733111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. International differences in approaches to 131I therapy for Graves' disease: case selection and restrictions recommended to patients in Japan, Korea, and China.
    Tominaga T; Yokoyama N; Nagataki S; Cho BY; Koh CS; Chen JL; Shi Y
    Thyroid; 1997 Apr; 7(2):217-20. PubMed ID: 9133688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Guidelines for radio-iodine (131I) therapy in Graves' disease and thyroid cancer].
    Mori Y; Kusakabe K; Ikekubo K; Ishikawa N; Nakada K; Kanaya S; Misaki T; Yokoyama K; Kubo A; Higashi T; Itou K; Noguchi Y; Tsuchimochi S; Togawa T;
    Kaku Igaku; 2005 Feb; 42(1):17-32. PubMed ID: 15794118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Radioiodine therapy in Europe--a survey].
    Schicha H; Scheidhauer K
    Nuklearmedizin; 1993 Dec; 32(6):321-4. PubMed ID: 8295830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radioiodine therapy in benign thyroid disorders. Evaluation of French nuclear medicine practices.
    Bernard D; Desruet MD; Wolf M; Roux J; Boin C; Mazet R; Gallazzini C; Calizzano A; Vuillez JP; Allenet B; Fagret D
    Ann Endocrinol (Paris); 2014 Sep; 75(4):241-6. PubMed ID: 25156133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Procedure guideline for therapy of thyroid disease with (131)iodine.
    Meier DA; Brill DR; Becker DV; Clarke SE; Silberstein EB; Royal HD; Balon HR;
    J Nucl Med; 2002 Jun; 43(6):856-61. PubMed ID: 12050333
    [No Abstract]   [Full Text] [Related]  

  • 8. Results of radioiodine (131/125I) therapy of hyperthyroidism.
    Glanzmann C; Horst W; Magdeburg W
    Radiol Clin (Basel); 1975; 44(5):484-90. PubMed ID: 1208842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Recent progress in radionuclide therapy].
    Kasagi K; Iwata M; Misaki T; Konishi J; Sakahara H
    Nihon Igaku Hoshasen Gakkai Zasshi; 2000 Nov; 60(13):729-37. PubMed ID: 11140321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thyroid fine-needle aspiration biopsy: which lesions should be biopsied before 131I therapy?
    Listewnik MH; Birkenfeld B; Chosia M; Elbl B; Piwowarska-Bilska H; Zorga P; Niedziałkowska K
    Ann Acad Med Stetin; 2011; 57(1):54-8. PubMed ID: 22593992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic 131I in outpatients: a simplified method conforming to the Code of Federal Regulations, title 10, part 35.75.
    Coover LR; Silberstein EB; Kuhn PJ; Graves MW
    J Nucl Med; 2000 Nov; 41(11):1868-75. PubMed ID: 11079497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. One-year follow-up of Graves' disease treatment by four different protocols of radioiodine administration.
    Calegaro JU; De Freitas Gomes E; Bae SH; Ulyssea R; Casulari LA
    Panminerva Med; 2000 Dec; 42(4):241-5. PubMed ID: 11294085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Radionuclide therapy of thyroid disease--radioactive iodine therapy].
    Kusakabe K; Maki M
    Kaku Igaku; 1993 Jul; 30(7):813-9. PubMed ID: 8377305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current safety practices relating to I-131 administration for diseases of the thyroid: a survey of physicians and allied practitioners.
    Greenlee C; Burmeister LA; Butler RS; Edinboro CH; Morrison SM; Milas M;
    Thyroid; 2011 Feb; 21(2):151-60. PubMed ID: 21275765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radionuclide therapy of the thyroid.
    Clarke SE
    Eur J Nucl Med; 1991; 18(12):984-91. PubMed ID: 1778212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A predictive mathematical model for the calculation of the final mass of Graves' disease thyroids treated with 131I.
    Traino AC; Di Martino F; Grosso M; Monzani F; Dardano A; Caraccio N; Mariani G; Lazzeri M
    Phys Med Biol; 2005 May; 50(9):2181-91. PubMed ID: 15843745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Release of patients after therapy with unsealed radionuclides.
    International Commission on Radiological Protection
    Ann ICRP; 2004; 34(2):v-vi, 1-79. PubMed ID: 15571759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radioiodine therapy in Graves' disease based on tissue-absorbed dose calculations: effect of pre-treatment thyroid volume on clinical outcome.
    Reinhardt MJ; Brink I; Joe AY; Von Mallek D; Ezziddin S; Palmedo H; Krause TM
    Eur J Nucl Med Mol Imaging; 2002 Sep; 29(9):1118-24. PubMed ID: 12192554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Experience with ambulatory radioiodine therapy of hyperthyroidism].
    Róka R; Séra T; Valkusz Z; Julesz J; Csernay L; Pávics L
    Orv Hetil; 1999 Jun; 140(23):1291-5. PubMed ID: 10412264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiation dose to patients and relatives incident to 131I therapy.
    Zanzonico PB
    Thyroid; 1997 Apr; 7(2):199-204. PubMed ID: 9133684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.